LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

InflaRx NV

Cerrado

0.84 2.44

Resumen

Variación precio

24h

Actual

Mínimo

0.81

Máximo

0.84

Métricas clave

By Trading Economics

Ingresos

-3.2M

-8.3M

BPA

-0.13

Margen de beneficio

1,208,456.738

Empleados

74

EBITDA

-3.2M

-8.2M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+602.41% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-54M

60M

Apertura anterior

-1.6

Cierre anterior

0.84

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

InflaRx NV Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

6 jun 2025, 14:31 UTC

Ganancias

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 jun 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 jun 2025, 20:33 UTC

Ganancias

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 jun 2025, 19:36 UTC

Charlas de Mercado

Oil Futures Post Solid Weekly Gains -- Market Talk

6 jun 2025, 19:28 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 jun 2025, 18:46 UTC

Charlas de Mercado

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 jun 2025, 18:02 UTC

Charlas de Mercado

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 jun 2025, 16:35 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 jun 2025, 16:34 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 jun 2025, 16:21 UTC

Charlas de Mercado

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 jun 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 jun 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 jun 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

6 jun 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 jun 2025, 16:07 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

6 jun 2025, 16:07 UTC

Charlas de Mercado

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 jun 2025, 15:53 UTC

Charlas de Mercado

Mexican Inflation Seen Rising in May -- Market Talk

6 jun 2025, 15:36 UTC

Charlas de Mercado

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 jun 2025, 15:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 jun 2025, 15:33 UTC

Charlas de Mercado

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 jun 2025, 15:16 UTC

Charlas de Mercado

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 jun 2025, 15:05 UTC

Charlas de Mercado

Silver at its Highest In Nearly 15 Years -- Market Talk

6 jun 2025, 14:35 UTC

Charlas de Mercado

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 jun 2025, 14:28 UTC

Charlas de Mercado

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 jun 2025, 14:28 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 jun 2025, 14:28 UTC

Charlas de Mercado

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 jun 2025, 14:15 UTC

Charlas de Mercado

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 jun 2025, 14:12 UTC

Ganancias

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 jun 2025, 14:09 UTC

Ganancias

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparación entre iguales

Cambio de precio

InflaRx NV Esperado

Precio Objetivo

By TipRanks

602.41% repunte

Estimación a 12 meses

Media 5.83 USD  602.41%

Máximo 10 USD

Mínimo 2 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para InflaRx NV Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

6

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.29 / 1.85Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de InflaRx NV

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.